Du är här

2016-05-16

Swedish Orphan Biovitrum AB: Sobi's CEO divests a portion of incentive shares

Swedish Orphan Biovitrum AB's (publ) (http://www.sobi.com) (Sobi™) CEO
Geoffrey McDonough has divested 230,000 of the shares he holds in the
company. The sale was made in part to pay the estimated US tax due
relating to the vesting of the company's 2013 long-term incentive
programme, and to prepare to invest in the upcoming 2016 long-term
incentive programme should it be approved by the Annual General
Meeting later this month.

The 2013 long-term incentive programme has met its objectives and will
vest in full. Geoffrey McDonough will receive 135,000 shares under
this programme. After the transactions, the CEO will hold a total of
647,845 shares in the company.

When receiving incentive shares, their fair market value will be taxed
as income at the time of allotment. In the US preliminary tax must be
remitted on the allotment date.

---

Terms and conditions of the proposed Sobi 2016 Executive long-term
incentive program can be found on www.sobi.com.

About Sobi™
Sobi™ is an international specialty healthcare company dedicated to
rare diseases. Our mission is to develop and deliver innovative
therapies and services to improve the lives of patients. The product
portfolio is primarily focused on Haemophilia, Inflammation and
Genetic diseases. We also market a portfolio of speciality and rare
disease products across Europe, the Middle East, North Africa and
Russia for partner companies. Sobi is a pioneer in biotechnology with
world-class capabilities in protein biochemistry and biologics
manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion
(USD 385 M) and approximately 700 employees. The share (STO:SOBI) is
listed on NASDAQ Stockholm.

For more information please contact

Media relations Investor relations
Oskar Bosson, Head of Jörgen Winroth, Vice
Communications President, Head of Investor
Relations
T: +46 70 410 71 80 T: +1 347-224-0819, +1 212
-579-0506, +46 8 697 2135
oskar.bosson@sobi.com jorgen.winroth@sobi.com

The information set out in this press release is announced in
accordance with the Swedish Securities Market Act. The information
was submitted for publication on 16 May 2016 at 08:30 CET.

-----------------------------------------------------------
http://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-s-ceo-divests-...
http://mb.cision.com/Main/14266/2009552/515981.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.